Nuwellis Highlights Aquadex Ultrafiltration Improving Pre- and Post-Transplant Outcomes in Pediatrics
Nuwellis showcased a University of Iowa case study at ISHLT demonstrating Aquadex SmartFlow achieved safe, precise ultrafiltration in a pediatric patient with chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload when diuretics failed. The therapy improved preoperative fluid status and post-transplant outcomes, supporting its pediatric cardiorenal care potential.
1. Case Study Presentation
Nuwellis featured a poster by University of Iowa investigators at the 46th Annual Meeting & Scientific Sessions of ISHLT, examining Aquadex SmartFlow therapy in a pediatric patient with chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload. The study evaluated feasibility, safety endpoints, and clinical impact when diuretics and medical management failed to prevent hospital readmissions.
2. Clinical Outcomes and Adoption Efforts
The ultrafiltration therapy delivered controlled, precise fluid removal that improved fluid status before surgery and enhanced post-transplant recovery, underscoring precision ultrafiltration’s importance in complex pediatric cardiorenal cases. Nuwellis emphasized its push for pediatric indication adoption and efforts to establish standardized fluid management protocols across clinical settings.